Multicenter, no-profit, open, single sequence cross-over study on effectiveness and safety of anti-rejection therapy based on modified release Tacrolimus(Advagraf)and on patients quality of life and adhesion to therapeutical regimen improvement after switch from conventional BID(Prograf) Tacrolimus immunosuppressive therapy to mono-administration of modified release of Tacrolimus in stable kidney transplant recipient

Trial Profile

Multicenter, no-profit, open, single sequence cross-over study on effectiveness and safety of anti-rejection therapy based on modified release Tacrolimus(Advagraf)and on patients quality of life and adhesion to therapeutical regimen improvement after switch from conventional BID(Prograf) Tacrolimus immunosuppressive therapy to mono-administration of modified release of Tacrolimus in stable kidney transplant recipient

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2014

At a glance

  • Drugs Tacrolimus (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms AQUARIUS
  • Most Recent Events

    • 04 May 2012 Actual initiation date (21 Feb 2011) added as reported by European Clinical Trials Database.
    • 04 May 2012 Planned end date (21 Oct 2012) added as reported by European Clinical Trials Database.
    • 23 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top